Silent Progression Activity Monitoring - SPAM Study
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Dec 5, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • INCLUSION CRITERIA: - Patients with RRMS (2017 Mc Donald criteria) treated with highly active treatment in the first 5 years of symptoms onset, at least 1 year, with an EDSS below 4
- • HAT start after April 12th 2007 (availability of Natalizumab)
- • Naive or failure (or intolerability) to 1 or more first line DMT (injectables, teriflunomide, DMF).
- * EDSS \< or equal 4 when starting HAT EXCLUSION CRITERIA:
- • Progressive relapsing MS at baseline
- • Clinical or basic MRI data unavailable after on-site visit.
- • MS diagnostic \> 5 years at baseline
- • Immunosuppressive drugs (Azathioprine, Cyclophosphamide, Mycophenolate, Methotrexate) prescribed before HAT initiation
About Centre Hospitalier Universitaire De Nice
The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials